Fosamax-Related Osteonecrosis of the Jaw: Biological Plausibility and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, discussions of bone health and pharmaceutical interventions have historically emphasized patient education and informed consent. As this informational heritage evolves, a natural progression emerges toward examining specific exposure scenarios that may carry distinct risk profiles. Transitioning from this general health framework, attention now turns to occupational and environmental exposure contexts. In mass production settings, workers may encounter materials or processes that involve compounds with biological activity, including those related to bone metabolism regulation. The shift from a patient-centered, prescription-based paradigm to an occupational exposure concern requires careful consideration of how chronic, low-level contact with certain substances might influence tissue health over extended periods. This bridge concept acknowledges that while general health information provides a baseline for understanding potential risks, the occupational environment introduces variables such as cumulative exposure duration, concentration gradients, and co-exposures that differ substantially from therapeutic use. The focus here is on the plausibility of biological pathways linking sustained exposure to adverse outcomes, without delving into specific disease mechanisms. This transition sets the stage for examining how mass production contexts may warrant distinct risk assessment approaches compared to clinical settings.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the general framework of occupational and environmental exposure, we now focus on a specific pharmaceutical agent: Fosamax (alendronate). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. While this effect is beneficial for increasing bone mass and reducing fracture risk, it has been associated with a rare but serious adverse event: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal after dental procedures. Diagnosis is based on clinical examination and imaging, with the hallmark being persistent bone exposure for more than eight weeks in the absence of prior radiation therapy to the jaws.

Biological Plausibility: Mechanistic Pathways

The biological plausibility linking Fosamax to ONJ is supported by several mechanistic pathways. Bisphosphonates, including alendronate, accumulate in bone tissue, particularly at sites of high bone turnover such as the jaw. The jawbone undergoes constant remodeling due to mechanical stress from chewing and the presence of teeth. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This research indicates that bisphosphonate treatment alters the mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These changes can impair the jawbone's ability to repair microdamage and respond to local infections or trauma. The primary mechanistic pathway involves the suppression of osteoclast activity. Osteoclasts are essential for bone remodeling, including the removal of necrotic bone and the initiation of new bone formation. By inhibiting osteoclast function, Fosamax reduces the turnover of jawbone, leading to an accumulation of microdamage and a decreased capacity to heal after dental procedures. Additionally, bisphosphonates have anti-angiogenic properties, which can reduce blood supply to the jawbone, further compromising healing. Local factors such as infection, inflammation, and dental extractions can trigger ONJ in patients with suppressed bone turnover.

Risk Factors and Clinical Evidence

Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Warning Adequacy

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning describes the association, risk factors, and clinical management considerations. The label advises discontinuation of the drug if severe symptoms develop and notes that most patients have relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the warning also states that in placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may lead to confusion about the actual risk. Causation considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ, excluding other causes such as radiation therapy or metastatic disease, and documenting the clinical course. The biological plausibility, supported by mechanistic studies and clinical reports, provides a foundation for causation. However, the rarity of ONJ and the presence of other risk factors complicate individual case assessments. Patients who develop ONJ while on Fosamax should be evaluated for modifiable risk factors, and dental care should be optimized to prevent further complications.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis and other bone conditions. It works by inhibiting osteoclast activity, which reduces bone resorption and turnover. This helps increase bone mass and reduce fracture risk, but can also lead to adverse effects such as osteonecrosis of the jaw.

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the jaw. It is a rare but serious adverse event associated with bisphosphonates like Fosamax. The biological plausibility involves suppression of bone turnover, accumulation of microdamage, and reduced blood supply, especially after dental procedures or local infection.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions such as periodontal disease, anemia, or infection. Duration of bisphosphonate use may also increase risk.

How long after starting Fosamax can ONJ occur?

The time to onset of symptoms can vary from one day to several months after starting the drug. Most patients experience relief after stopping the medication, but some may have recurrence if rechallenged with the same or another bisphosphonate.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.